Dr. Xichen Lin has been the Asia Pacific head of Search & Evaluation in Novo Nordisk since 2016. In this role, he is responsible for identifying external innovation and driving maturation through collaboration with academic and biotech companies in China, South Korea, Japan, Australia and Singapore. He also works closely with Novo Nordisk global BD in various deal makings through open innovation, licensing, co-development and collaboration.
Prior to Novo Nordisk, Xichen worked for GlaxoSmithKline for almost 15 years with increased responsibility as head of chemistry, head of neuro-inflammation Discovery Performance Unit and Director of External Innovation in both Shanghai and Philadelphia. He was responsible for establishing and coordinating a scientific network with research institutes and biotech companies in China to identify targets and programs to support GSK’s pipeline. Overall, he has successfully led programs that yielded six clinical candidates within respiratory, inflammation and neuroscience areas.
Xichen received B.S. degree from Peking University in chemistry and Ph.D. from the Pennsylvania State University in total synthesis. He has more than 30 publications and 20 patent applications, and also lectures in Shanghai Jiaotong University School of Pharmacy and Peking University College of Chemistry and Molecular Engineering.